What is the clinical evidence from this study?

Study design: Other. Population: Cardiac hypertrophy. Intervention: Atorvastatin vs. Angiotensin II stimulation alone. Primary outcome: Cardiomyocyte hypertrophy (myocyte surface area, 3H-leucine incorporation, and expression of ANP and BNP).

December 1, 2015Chinese Medical Sciences Journal

Atorvastatin ameliorated Ang II-induced neonatal cardiomyocyte hypertrophy and inhibited cytokine expression, partly through activation of the PPAR-δ/β pathway.

View Full Paper

Ask AI

Bookmark

Population

In vitro cultured neonatal rat cardiomyocytes with hypertrophy induced by angiotensin II (Ang II) stimulation

Design

Preclinical

Key result

Atorvastatin ameliorated Ang II-induced neonatal cardiomyocyte hypertrophy and inhibited cytokine expression, partly through activation of the PPAR-δ/β pathway.

Authors

LSLi Sheng YXYang Xu PYPing Ye

Discussion

Member takes

Overview

May inform mechanistic research on atorvastatin in hypertrophy; leaves open in vivo and clinical translation.

Structured PICO

Population

In vitro model of neonatal rat cardiomyocytes stimulated with angiotensin II to induce hypertrophy.

Intervention

Atorvastatin pretreatment at concentrations of 0.1, 1, and 10 μmol/L

Outcome

Myocyte surface area, 3H-leucine incorporation, mRNA expressions of atrial natriuretic peptide, brain natriuretic peptide, matrix metalloproteinase 9, matrix metalloproteinase 2, and interleukin-1β, and mRNA and protein expressions of the δ/β peroxisome proliferator-activated receptor (PPAR) subtypessurrogate

Atorvastatin attenuates angiotensin II-induced cardiomyocyte hypertrophy in vitro, potentially through the activation of the PPAR-δ/β pathway.

Cite This Study

Sheng et al. (2015) studied Cardiac hypertrophy. Atorvastatin vs. Angiotensin II stimulation alone was evaluated on Cardiomyocyte hypertrophy (myocyte surface area, 3H-leucine incorporation, and expression of ANP and BNP). Atorvastatin ameliorated Ang II-induced neonatal cardiomyocyte hypertrophy and inhibited cytokine expression, partly through activation of the PPAR-δ/β pathway.

synapsesocial.com/papers/6a21436ca2a97f3a085ae042 https://doi.org/10.1016/s1001-9294(16)30008-6

View Full Paper

Ask AI

Bookmark

December 1, 2015Chinese Medical Sciences Journal

Atorvastatin ameliorated Ang II-induced neonatal cardiomyocyte hypertrophy and inhibited cytokine expression, partly through activation of the PPAR-δ/β pathway.

View Full Paper

Ask AI

Bookmark

Population

In vitro cultured neonatal rat cardiomyocytes with hypertrophy induced by angiotensin II (Ang II) stimulation

Design

Preclinical

Key result

Atorvastatin ameliorated Ang II-induced neonatal cardiomyocyte hypertrophy and inhibited cytokine expression, partly through activation of the PPAR-δ/β pathway.

Authors

LSLi Sheng YXYang Xu PYPing Ye

Discussion

Member takes

Overview

May inform mechanistic research on atorvastatin in hypertrophy; leaves open in vivo and clinical translation.

Structured PICO

Population

In vitro model of neonatal rat cardiomyocytes stimulated with angiotensin II to induce hypertrophy.

Intervention

Atorvastatin pretreatment at concentrations of 0.1, 1, and 10 μmol/L

Outcome

Atorvastatin attenuates angiotensin II-induced cardiomyocyte hypertrophy in vitro, potentially through the activation of the PPAR-δ/β pathway.

Cite This Study

synapsesocial.com/papers/6a21436ca2a97f3a085ae042 https://doi.org/10.1016/s1001-9294(16)30008-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark